| Systematic (IUPAC) name | |
|---|---|
| (E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 538-79-4 |
| ATC code | None |
| PubChem | CID 5310967 |
| UNII | 6H35LF645A |
| Chemical data | |
| Formula | C10H14N2 |
| Mol. mass | 162.232 |
| SMILES | eMolecules & PubChem |
| |
|
Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease,[1][2] but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis.[3] Rivanicline also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release,[4] and so it could potentially also have other applications.
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)